Esmaili Neda, Bradfield Yasmin S
School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53705, USA.
Ophthalmology. 2007 Sep;114(9):1773-8. doi: 10.1016/j.ophtha.2006.12.015. Epub 2007 Mar 21.
To report 4 pediatric Down syndrome patients with optic nerve elevation and pseudotumor cerebri.
Retrospective observational case series.
Four pediatric Down syndrome patients found to have optic nerve elevation on ophthalmologic examination at a single institution.
Medical record review of 117 pediatric Down syndrome patients aged 0 to 18 years was performed. All patients were seen at the University of Wisconsin pediatric ophthalmology clinic between 1995 and 2005.
Visual acuity, optic nerve appearance, and neurologic work-up.
Four (3.4%) of 117 Down syndrome patients seen at the university's pediatric ophthalmology clinic were found to have optic nerve elevation. This included 2 boys and 2 girls, aged 2 to 10 years. None of the patients had a history of headache or transient visual obscuration. One of the patients had high hyperopia at the time of presentation, and all were referred for neurologic evaluation of suspected increased intracranial pressure. Three patients were diagnosed with pseudotumor cerebri (PTC) based on a normal brain magnetic resonance imaging (MRI) scan, an elevated opening cerebrospinal fluid (CSF) pressure on lumbar puncture, and normal CSF analysis results. The fourth patient's elevated optic nerve appearance was likely secondary to PTC after obtaining normal brain MRI results; however, this patient did not undergo a lumbar puncture. One child with PTC demonstrated improvement in visual acuity and optic nerve appearance after acetazolamide and weight loss therapy. The 2 additional patients with PTC were treated with either low-dose acetazolamide or weight loss therapy and experienced optic atrophy. The final patient, who did not undergo lumbar puncture, experienced spontaneous resolution of optic nerve elevation. Mean follow-up duration was 49 months.
Only 3.4% (4/117) of Down syndrome children were found to have optic nerve elevation in a single institution. Pseudotumor cerebri should be considered in asymptomatic Down syndrome patients with elevated optic nerves. Medical therapy in PTC with acetazolamide can lead to improvement in visual acuity and optic nerve appearance, although optic atrophy also was seen.
报告4例患有视神经抬高和假性脑瘤的小儿唐氏综合征患者。
回顾性观察病例系列。
在单一机构接受眼科检查时发现视神经抬高的4例小儿唐氏综合征患者。
对117例年龄在0至18岁的小儿唐氏综合征患者的病历进行回顾。所有患者均于1995年至2005年间在威斯康星大学小儿眼科诊所就诊。
视力、视神经外观及神经系统检查。
在该大学小儿眼科诊所就诊的117例唐氏综合征患者中,有4例(3.4%)被发现视神经抬高。其中包括2名男孩和2名女孩,年龄在2至10岁之间。所有患者均无头痛或短暂性视力模糊病史。1例患者在就诊时患有高度远视,所有患者均因怀疑颅内压升高而被转诊进行神经系统评估。3例患者基于正常的脑部磁共振成像(MRI)扫描、腰椎穿刺时脑脊液(CSF)初压升高以及正常的CSF分析结果被诊断为假性脑瘤(PTC)。第4例患者在脑部MRI结果正常后,其视神经抬高可能继发于PTC;然而,该患者未接受腰椎穿刺。1例患有PTC的儿童在接受乙酰唑胺和减重治疗后,视力和视神经外观有所改善。另外2例患有PTC的患者接受了低剂量乙酰唑胺或减重治疗,但出现了视神经萎缩。最后1例未接受腰椎穿刺的患者,其视神经抬高自行消退。平均随访时间为49个月。
在单一机构中,仅3.4%(4/117)的唐氏综合征儿童被发现视神经抬高。对于无症状的视神经抬高的唐氏综合征患者,应考虑假性脑瘤。PTC采用乙酰唑胺进行药物治疗可使视力和视神经外观有所改善,尽管也出现了视神经萎缩。